Related Experiment Video
Updated: Mar 3, 2026
07:17
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
12.8K
Does Recurrent Pancreatic Cancer Have Similar Outcomes Compared With Primary Metastatic Pancreatic Cancer?
Shinya Sakamoto1, Motoyasu Tabuchi1, Teppei Tokumaru1
1Department of Gastroenterological Surgery, Kochi Health Sciences Center, Kochi, Japan.
Journal of Surgical Oncology
|March 2, 2026
Summary
Recurrent pancreatic cancer patients showed significantly longer overall survival than those with primary metastatic disease. Recurrent pancreatic cancer is a favorable prognostic factor in advanced cases.
Area of Science:
- Oncology
- Medical Oncology
- Cancer Research
Background:
- The survival outcomes between recurrent pancreatic cancer (Rec-PC) and primary metastatic pancreatic cancer (PM-PC) require further clarification.
- Pancreatic cancer is a leading cause of cancer-related mortality, necessitating research into prognostic factors.
Purpose of the Study:
- To compare the overall survival (OS) between patients with Rec-PC and PM-PC.
- To identify independent prognostic factors influencing survival in advanced pancreatic cancer.
Main Methods:
- Retrospective analysis of 147 patients treated with gemcitabine plus nab-paclitaxel (GnP) or FOLFIRINOX chemotherapy.
- Comparison of OS between Rec-PC and PM-PC groups.
Main Results:
- Rec-PC patients had significantly longer median OS (12.7 months) compared to PM-PC patients (8.4 months) (p=0.03).
- Independent prognostic factors included Rec-PC (HR: 0.51), peritoneal dissemination (HR: 2.29), second-line chemotherapy (HR: 0.34), local therapy (HR: 0.42), and prognostic nutritional index < 40 (HR: 2.50).
Conclusions:
- Recurrent pancreatic cancer is a favorable prognostic indicator in advanced pancreatic cancer, even after adjusting for other known prognostic factors.
- These findings aid in risk stratification and treatment planning for pancreatic cancer patients.
